These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 32977361

  • 1. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
    Qiu J, Zhang S, Wang P, Wang H, Sha B, Peng H, Ju Z, Rao J, Lu L.
    Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
    [Abstract] [Full Text] [Related]

  • 2. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C, Wang X, Fang D, Xu P, Mo X, Hu C, Abdelatty A, Wang M, Xu H, Sun Q, Zhou G, She J, Xia J, Hui KM, Xia H.
    Theranostics; 2021 Nov; 11(5):2108-2122. PubMed ID: 33500714
    [Abstract] [Full Text] [Related]

  • 3. Sp2 promotes invasion and metastasis of hepatocellular carcinoma by targeting TRIB3 protein.
    Zhu Y, Cui J, Liu J, Hua W, Wei W, Sun G.
    Cancer Med; 2020 May; 9(10):3592-3603. PubMed ID: 32160655
    [Abstract] [Full Text] [Related]

  • 4. Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients.
    Zhuang L, Yang Z, Meng Z.
    Biomed Res Int; 2018 May; 2018():7897346. PubMed ID: 30363964
    [Abstract] [Full Text] [Related]

  • 5. Expression and Clinical Role of Cdc5L as a Novel Cell Cycle Protein in Hepatocellular Carcinoma.
    Qiu H, Zhang X, Ni W, Shi W, Fan H, Xu J, Chen Y, Ni R, Tao T.
    Dig Dis Sci; 2016 Mar; 61(3):795-805. PubMed ID: 26553251
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression.
    Yu Y, Chen X, Zhang W, Liu J.
    Biomed Res Int; 2021 Mar; 2021():4051192. PubMed ID: 34957303
    [Abstract] [Full Text] [Related]

  • 8. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
    Tian F, Cai D.
    Gene; 2022 Jan 10; 807():145964. PubMed ID: 34530087
    [Abstract] [Full Text] [Related]

  • 9. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM, Hu L, Gu J, Wang RY, Li L, Tang J, Zhang BH, Yan XZ, Zhu YJ, Hu CL, Zhou WP, Li S, Liu JF, Gonzalez FJ, Wu MC, Wang HY, Chen L.
    Gastroenterology; 2017 Apr 10; 152(5):1187-1202. PubMed ID: 28065789
    [Abstract] [Full Text] [Related]

  • 10. STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma.
    Lan Y, Han J, Wang Y, Wang J, Yang G, Li K, Song R, Zheng T, Liang Y, Pan S, Liu X, Zhu M, Liu Y, Meng F, Mohsin M, Cui Y, Zhang B, Subash S, Liu L.
    Cell Death Dis; 2018 Feb 14; 9(2):236. PubMed ID: 29445189
    [Abstract] [Full Text] [Related]

  • 11. SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway.
    Fan Y, Du Z, Ding Q, Zhang J, Op Den Winkel M, Gerbes AL, Liu M, Steib CJ.
    Int J Oncol; 2021 Jun 14; 58(6):. PubMed ID: 33846777
    [Abstract] [Full Text] [Related]

  • 12. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway.
    Yang J, Zhang X, Liu L, Yang X, Qian Q, Du B.
    Life Sci; 2021 Jan 01; 264():118711. PubMed ID: 33186566
    [Abstract] [Full Text] [Related]

  • 13. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
    Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M.
    Gastroenterology; 2011 Mar 01; 140(3):1071-83. PubMed ID: 21147110
    [Abstract] [Full Text] [Related]

  • 14. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
    Zhang S, Zhou YF, Cao J, Burley SK, Wang HY, Zheng XFS.
    Cancer Res; 2021 Nov 15; 81(22):5652-5665. PubMed ID: 34429326
    [Abstract] [Full Text] [Related]

  • 15. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
    Wang J, Xia C, Pu M, Dai B, Yang X, Shang R, Yang Z, Zhang R, Tao K, Dou K.
    Oncol Rep; 2018 Oct 15; 40(4):1875-1884. PubMed ID: 30015982
    [Abstract] [Full Text] [Related]

  • 16. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.
    Gastroenterology; 2016 Dec 15; 151(6):1192-1205. PubMed ID: 27614046
    [Abstract] [Full Text] [Related]

  • 17. Overexpression of Rab5a promotes hepatocellular carcinoma cell proliferation and invasion via FAK signaling pathway.
    Geng D, Zhao W, Feng Y, Liu J.
    Tumour Biol; 2016 Mar 15; 37(3):3341-7. PubMed ID: 26443539
    [Abstract] [Full Text] [Related]

  • 18. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.
    Zheng Y, Jiang L, Hu Y, Xiao C, Xu N, Zhou J, Zhou X.
    BMC Cancer; 2017 Feb 28; 17(1):161. PubMed ID: 28241806
    [Abstract] [Full Text] [Related]

  • 19. LncRNA DCST1-AS1 accelerates the proliferation, metastasis and autophagy of hepatocellular carcinoma cell by AKT/mTOR signaling pathways.
    Li J, Zhai DS, Huang Q, Chen HL, Zhang Z, Tan QF.
    Eur Rev Med Pharmacol Sci; 2019 Jul 28; 23(14):6091-6104. PubMed ID: 31364110
    [Abstract] [Full Text] [Related]

  • 20. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
    Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, Nan K, Yao Y, Tian T.
    Cancer Sci; 2017 Apr 28; 108(4):620-631. PubMed ID: 28132399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.